Viyash Scientific Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2026.
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Viyash Scientific Limited's Board approved audited Q4 and FY26 financial results. On a consolidated basis, FY26 revenue was Rs 34,203.10 million with profit after tax of Rs 3,490.20 million, compared to Rs 30,068.40 million revenue and Rs 131.80 million PAT in FY25 (restated after amalgamation). The improvement reflects a large jump in profitability year-on-year. The Board approved adoption of new Articles of Association (subject to shareholder approval) and granted 1,30,98,000 stock options to employees under the Viyash Scientific Limited Employee Stock Option Scheme 2026. No dividend was recommended for FY 2025-26. The Composite Scheme of Amalgamation (approved by NCLT in November 2025, effective December 2025) has been given effect in these results, with prior periods restated. The auditors issued an unmodified opinion on the financial statements.
The company posted strong consolidated profit growth in FY26 compared to FY25, boosted by the amalgamation with Viyash Life Sciences and subsidiaries. The large stock option grant may have a dilution impact. The absence of dividend may disappoint income-focused investors.